Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment of erectile dysfunction.

Wallace Dinsmore1

  • 1Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, UK. wallacedinsmore@hotmail.com

International Journal of STD & AIDS
|April 13, 2004
PubMed
Summary

Erectile dysfunction (ED) is a common condition often undertreated. Oral phosphodiesterase-5 (PDE5) inhibitors like tadalafil offer effective treatment, improving quality of life and sexual function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Chlamydia trachomatis</i> conjunctivitis in the pre-pubertal child.

Archives of disease in childhood. Education and practice edition·2022
Same author

Persistent genital arousal and restless genitalia: sexual dysfunction or subtype of vulvodynia?

International journal of STD & AIDS·2013
See all related articles

Area of Science:

  • Urology
  • Andrology
  • Pharmacology

Background:

  • Erectile dysfunction (ED) is prevalent yet frequently underdiagnosed and undertreated.
  • ED stems from diverse factors including vascular, neurological, hormonal, and psychological origins.
  • Successful ED treatment aims to restore patient quality of life and sexual activity.

Purpose of the Study:

  • To review current therapeutic options for erectile dysfunction.
  • To highlight the role and efficacy of oral phosphodiesterase-5 (PDE5) inhibitors.
  • To compare available PDE5 inhibitors, focusing on efficacy, safety, and patient convenience.

Main Methods:

  • Literature review of current ED treatments.
  • Analysis of clinical data on PDE5 inhibitors (sildenafil, vardenafil, tadalafil).
  • Comparative assessment of efficacy, safety profiles, and pharmacokinetic properties.

Main Results:

  • Oral phosphodiesterase-5 (PDE5) inhibitors represent a first-line therapy for ED.
  • Sildenafil, vardenafil, and tadalafil demonstrate similar efficacy and favorable safety profiles.
  • Tadalafil offers a unique advantage with a longer duration of action, enhancing treatment flexibility.

Conclusions:

  • PDE5 inhibitors have significantly advanced ED management.
  • All available PDE5 inhibitors are effective, but tadalafil provides enhanced patient convenience.
  • Optimal ED treatment choice should consider individual patient needs and lifestyle.

Related Experiment Videos